Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th
September 09, 2020 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts
August 20, 2020 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform
August 07, 2020 07:30 ET
|
Orgenesis Inc.
Provides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020 GERMANTOWN, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc....
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells
July 14, 2020 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis Added to Russell 3000® Index
June 29, 2020 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19
June 22, 2020 08:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19
June 10, 2020 09:07 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of Tumor Infiltrating Lymphocytes
June 01, 2020 09:38 ET
|
Orgenesis Inc.
GERMANTOWN, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Announces Collaboration with Hospital Infantil Universitario Niño Jesús, Madrid, to Establish Point of Care Center
May 22, 2020 09:11 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis Announces Stock Repurchase Plan of Up to $10 Million
May 15, 2020 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...